{
  "ticker": "NEU",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02977908",
  "id": "02977908",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250807",
  "time": "0951",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250807/pdf/06mmlyms1pllz0.pdf",
  "summary": "**Summary of Material Information (Neuren Pharmaceuticals \u2013 ASX Announcement 7 August 2025):**  \n\n- **Q2 2025 DAYBUE\u2122 (trofinetide) net sales**: US$96.1 million, up **14% YoY** (Q2 2024) and **14% QoQ** (Q1 2025).  \n- **Royalty income to Neuren**: A$14.7 million (Q2 2025), up **16% YoY** and **9% QoQ**.  \n- **Full-year 2025 guidance (Acadia)**: DAYBUE US net sales of **US$380\u2013405 million**, implying **A$62\u201367 million** royalty income for Neuren (AUD/USD 0.65).  \n- **Commercial progress**:  \n  - Record patient shipments (987 in Q2, up from 954 in Q1).  \n  - Acadia expanded sales force by **~30%** and initiated named patient programs in **Europe** and **Rest of World**.  \n  - European approval expected **Q1 2026**.  \n\n*Note: No material updates on capital structure, liquidity, or other valuation-sensitive items.*",
  "usage": {
    "prompt_tokens": 1594,
    "completion_tokens": 258,
    "total_tokens": 1852,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-08-07T00:21:59.834802"
}